Want to see IN:SANOFI full AI Analyst Report?
Top Page
Sanofi India Limited
(SANOFI)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹3,663.00
▲(14.81% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by strong financial quality (very low leverage and strong cash generation). This is tempered by weakening revenue and margin compression, and by a mixed technical picture with the stock trading below key moving averages. Valuation is reasonable but not compelling, with the dividend yield providing support against a mid-20s P/E.
Positive Factors
Very low leverage / strong balance sheet
A very low debt-to-equity ratio (~1–2% historically, ~2% in 2025) gives durable financial flexibility. It reduces solvency risk, supports investment or M&A optionality, and allows the company to weather industry cycles without stressing cash flow or requiring costly refinancing.
Negative Factors
Weakened revenue growth trajectory
A multi-year pattern of choppy top-line performance and a 2025 revenue decline indicate weakening organic demand or competitive/market pressures. Persistent revenue softness harms scale economies and limits ability to grow operating profit absent margin recovery or new product drivers.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / strong balance sheet
A very low debt-to-equity ratio (~1–2% historically, ~2% in 2025) gives durable financial flexibility. It reduces solvency risk, supports investment or M&A optionality, and allows the company to weather industry cycles without stressing cash flow or requiring costly refinancing.
Read all positive factors
Sanofi India Limited (SANOFI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹71.50B
Dividend Yield3.96%
Average Volume (3M)1.99K
Price to Earnings (P/E)22.1
Beta (1Y)0.75
Revenue Growth-8.88%
EPS Growth-10.68%
CountryIN
Employees1,097
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)98.01
Shares Outstanding23,030,000
10 Day Avg. Volume2,067
30 Day Avg. Volume1,993
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)166.9
Revenue Forecast (FY)₹19.51B
Sanofi India Limited Business Overview & Revenue Model
Company Description
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infecti...
How the Company Makes Money
Sanofi India Limited primarily makes money by selling pharmaceutical and healthcare products in India. Its core revenue stream is the sale of prescription medicines (Rx) across various therapeutic categories, typically distributed through pharmace...
Sanofi India Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
90
Very Positive
Cash Flow
82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 18.37B | 20.13B | 19.96B | 27.70B | 29.57B |
| Gross Profit | 7.18B | 10.19B | 10.31B | 15.65B | 16.33B |
| EBITDA | 4.84B | 4.85B | 4.85B | 6.98B | 7.54B |
| Net Income | 3.27B | 4.13B | 6.03B | 6.21B | 9.44B |
Balance Sheet | |||||
| Total Assets | 12.55B | 16.12B | 17.15B | 20.72B | 30.61B |
| Cash, Cash Equivalents and Short-Term Investments | 2.75B | 3.40B | 3.94B | 10.05B | 15.38B |
| Total Debt | 178.00M | 193.00M | 190.00M | 236.00M | 246.00M |
| Total Liabilities | 5.06B | 7.51B | 7.00B | 7.96B | 8.35B |
| Stockholders Equity | 7.49B | 8.61B | 10.15B | 12.76B | 22.26B |
Cash Flow | |||||
| Free Cash Flow | 4.25B | 4.25B | 1.96B | 3.77B | 5.36B |
| Operating Cash Flow | 4.51B | 4.62B | 2.30B | 3.99B | 5.59B |
| Investing Cash Flow | -253.00M | -192.00M | 375.00M | 6.51B | 6.31B |
| Financing Cash Flow | -4.46B | -3.92B | -8.78B | -15.83B | -8.49B |
Sanofi India Limited Technical Analysis
Negative
3190.50
Price Trends
3307.65
Negative
3303.56
Negative
3601.77
Negative
Market Momentum
-52.72
Positive
34.83
Neutral
11.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SANOFI, the sentiment is Negative. The current price of 3190.5 is below the 20-day moving average (MA) of 3202.19, below the 50-day MA of 3307.65, and below the 200-day MA of 3601.77, indicating a bearish trend. The MACD of -52.72 indicates Positive momentum. The RSI at 34.83 is Neutral, neither overbought nor oversold. The STOCH value of 11.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SANOFI.
Sanofi India Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ₹190.83B | 25.49 | ― | 1.83% | 10.69% | -9.09% | |
73 Outperform | ₹535.98B | 33.24 | ― | 2.08% | 6.29% | 11.18% | |
73 Outperform | ₹1.11T | 32.90 | ― | 2.10% | 1.85% | -37.51% | |
70 Outperform | ₹71.50B | 22.09 | ― | 3.96% | -8.88% | -10.68% | |
68 Neutral | ₹488.93B | 45.06 | ― | 2.01% | 5.75% | 12.41% | |
65 Neutral | ₹499.01B | 43.01 | ― | 0.68% | 17.57% | 46.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:SANOFI
Sanofi India Limited
3,107.00
-1,828.33
-37.05%
IN:ABBOTINDIA
Abbott India Limited
25,272.60
-4,995.76
-16.50%
IN:CIPLA
Cipla Ltd
1,380.00
-166.38
-10.76%
IN:GLAND
Gland Pharma Ltd.
2,948.25
997.46
51.13%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,840.80
47.94
1.72%
IN:PFIZER
PFIZER LIMITED
4,096.25
-987.23
-19.42%
Sanofi India Limited Corporate Events
Sanofi India to Brief Investors on Q2 FY26 Unaudited Results
Aug 5, 2026
Sanofi India Limited has notified the stock exchanges that it will present an analyst and investor call update covering its unaudited financial results for the quarter and half year ended 30 June 2026. The company has circulated the presentation t...
Sanofi India Publishes Q1 and Half-Year FY2026 Financial Results in Newspapers
Aug 5, 2026
Sanofi India Limited has reported its unaudited financial results for the quarter and half year ended 30 June 2026 and published them in leading English and Marathi newspapers in line with SEBI listing regulations. The disclosure reinforces the co...
Sanofi India Board Clears Q2 FY2026 Results and Reshapes Key Committees
Aug 4, 2026
Sanofi India Limited’s board has approved the unaudited financial results for the quarter and half year ended 30 June 2026, fulfilling key regulatory requirements under SEBI’s Listing Regulations. The results, supported by a limited re...
Sanofi India posts robust Q2 2026 results, revamps board committees
Aug 4, 2026
Sanofi India reported strong unaudited financial results for the quarter and half year ended 30 June 2026, driven by double-digit growth in its diabetes portfolio and solid profit momentum, underscoring the strategic importance of chronic care in ...
Sanofi India Board Clears Q2 Results, Revamps Key Committees
Aug 4, 2026
Sanofi India Limited, a major player in India’s pharmaceutical and healthcare sector, provides prescription drugs and related therapies and is listed on both BSE and NSE. Its governance framework features specialised committees that oversee ...
Sanofi India Board Clears Q2 FY26 Results, Revamps Committees Ahead of CFO Exit
Aug 4, 2026
Sanofi India Limited’s board has approved the unaudited financial results for the quarter and half year ended June 30, 2026, which will be released to investors via stock exchange filings, newspaper extracts and the company’s website, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.